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Summary
Lack of an accepted definition for ‘high immunological risk’ hampers individuali-
zation of immunosuppressive therapy after kidney transplantation. For recipient-
related risk factors for acute rejection, the most compelling evidence points to
younger age and African American ethnicity. Recipient gender, body mass, previ-
ous transplantation, and concomitant infection or disease do not appear to be
influential. Deceased donation now has only a minor effect on rejection risk, but
older donor age remains a significant predictor. Conventional immunological
markers (human leukocyte antigen [HLA] mismatching, pretransplant anti-HLA
alloantibodies, and panel reactive antibodies) are being reassessed in light of
growing understanding about the role of donor-specific antibodies (DSA). At the
time of transplant, delayed graft function is one of the most clear-cut risk factors
for acute rejection. Extended cold ischemia time (≥24 h) may also play a contrib-
utory role. While it is not yet possible to establish conclusively the relative contri-
bution of different risk factors for acute rejection after kidney transplantation, the
available data point to variables that should be taken into account at the time of
transplant. Together, these offer a realistic basis for planning an appropriate
immunosuppression regimen in individual patients.
Introduction
Management of kidney transplant patients aims to achieve
the minimum level of immunosuppression to prevent graft
rejection. While the incidence of acute rejection has
approximately halved in the last decade [1] and now affects
only approximately 10–15% of patients in the first year
post-transplant, depending on the immunosuppressive
strategy [1,2], both cellular and antibody-mediated rejec-
tion continue to adversely affect allograft survival [3–5]. An
analysis of over 27 000 adult kidney transplant patients
from the United States Renal Data System (USRDS)
showed that acute rejection was associated with a 1.6-fold
increase in death-censored graft loss [3], while combined
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cellular and antibody-mediated rejection may increase graft
loss by as much as sixfold [4].
A reliable definition of immunological risk at the time of
transplantation would refine clinicians’ ability to individu-
alize therapy and avoid acute rejection without excessive
immunosuppression. It would also permit a more rational
risk stratification of patients in clinical trials of immuno-
suppression regimens. Currently, however, there is no
accepted definition of ‘high immunological risk’ and a lack
of consensus regarding the importance of individual risk
factors and cutoff points to define risk [6,7]. In recent ran-
domized trials of immunosuppressive regimens undertaken
in ‘high immunological risk’ populations, the criteria for
inclusion varied considerably [8–12]. Efforts to develop a
definition of high immunological risk are hampered by the
fact that multicenter studies or registry databases are often
necessary to provide adequate numbers for meaningful
analysis, and the endpoint of such studies is typically all-
cause or death-censored graft survival instead of acute
rejection. Moreover, large-scale analyses have usually
focused on the effect of one specific risk factor [e.g., obesity
or cytomegalovirus (CMV) infection], while ignoring other
potentially relevant factors. Lastly, studies of this type are
rarely able to base assessments on biopsy-proven acute
rejection and are instead obliged to rely on clinically sus-
pected or treated rejection.
This article reviews factors that may contribute substan-
tially to increased immunological risk and offers a qualita-
tive grading of their likely impact, with the supporting
evidence. Only variables that are known at the time of
transplantation are considered because these determine the
immunosuppression plan and, in clinical trials, risk catego-
rization of patients. A systematic assessment and citation of
all publications related to such a wide range of topics was
not considered feasible. Instead, we focused on large-scale
multivariate analyses where possible.
Recipient clinical characteristics
Of the various demographic and clinical characteristics of
kidney transplant recipients that may influence the risk of
acute rejection, the most compelling data relate to younger
age [3,4,13–17]. Different cutoff points have been used, but
45–50 years appear to be a relevant threshold for a signifi-
cant association with risk of rejection (Table 1). It should
be borne in mind when determining the initial immuno-
suppressive regimen, however, that although the risk of
rejection declines in older recipients, rejection appears to
have a greater impact on risk of graft loss so adequate rejec-
tion prophylaxis may be particularly critical [20]. Evidence
for an effect of gender after adjustment for confounding
variables in multivariate analyses is by no means consistent
[3,4,13–19] (Table 1), despite perceptions that female
patients have a greater propensity for rejection. Obesity
could potentially predispose to acute rejection due to an
effect on immunosuppressive drug disposition. However,
an analysis of United Network for Organ Sharing (UNOS)
data undertaken specifically to examine the effect of body
mass index (BMI) on outcomes reported that only the
highest category of BMI (≥35 kg/m2) was associated with
acute rejection at 1 year compared with normal weight
(OR 1.20, 95% CI 1.04–1.39; P = 0.014) [15].
Few studies have included an adequate number of non-
Caucasian recipients to evaluate the effect of race, but two
very large registry analyses of United States populations by
Cole et al. [3] and Gore et al. [15] both convincingly
Table 1. Recipient risk factors for acute rejection after kidney transplantation based on multivariate analysis.
Reference Data source
Year of
transplant n Younger age Gender
African
American High BMI Retransplant
CMV
serology/
infection
Dunn et al. [4] Single center 2004–2007 587 ✓ (<50 years) X – – X –
Cole et al. [3] USRDS 1995–2002 27 707 ✓ (<45 years) ✓ (male) ✓ X n/a –
Øien et al. [13] Single center 1994–2004 739 ✓ (<50 years) ✓ (female) – – n/a –
Quiroga et al. [14] Single center 1990–1998 518 ✓ – – – X X
Gore et al. [15] OPTN 1997–1999 27 377 ✓ ✓ (female) ✓ ✓ (morbid
obesity)
– –
Pallardo
Mateu et al. [16]
Multicenter 1990–1998 3365 ✓ (<60 years) X – – X ✓
Mota et al. [17] Single center 1985–1999 866 ✓ (<45 years) – – X – –
Sagedal et al. [18] Single center 1994–1997 477 X X – – X X
Boom et al. [19] Single center 1983–1997 734 X X – – X –
✓, indicates that a significant association was observed; X, indicates that no significant association was observed; –, indicates that no assessment was
made; n/a, not applicable; BMI, body mass index; CMV, cytomegalovirus; OPTN, Organ Procurement and Transplant Network; USRDS, United States
Renal Data System.
Cutoff values for continuous variables are shown in italics.
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demonstrated that black recipients are 22–25% more likely
to experience rejection than white recipients, a difference
that was statistically significant in both studies. A compari-
son of rejection rates by Schold et al., based on 112 120
kidney transplant patients in the Scientific Renal Trans-
plant Registry (SRTR) in the United States has suggested
that this difference may be confined to younger patients:
among patients aged 18–33 years, the adjusted OR for
acute rejection in African Americans versus white recipients
was 1.33 (95% CI 1.12–1.57), but diminished with age and
became nonsignificant in patients >65 years [21]. Gore
et al. also observed a significant reduction in risk in His-
panic versus non-Hispanic recipients (parameter estimate -
0.28, P = 0.01), but corroborative data are lacking. It
should be noted that none of these studies included non-
clinical factors in their models, such as socioeconomic sta-
tus, level of education, or access to health care (other than
health insurance in the study by Schold et al.), which are
known to influence compliance [22] and thus rejection
risk.
Perhaps surprisingly, several studies have shown no sig-
nificant association between previous kidney transplanta-
tion and risk of rejection [4,14,16,18,19,23]. Each of these
analyses, however, adjusted rejection rates for at least one
marker of sensitization in the multivariate analysis (pres-
ence of panel reactive antibodies [PRA], HLA mismatch,
or donor-specific antibodies [DSA]) that is, retransplanta-
tion per se was not a risk factor but the accompanying
HLA immunization must of course be taken into account
(See Recipient immunological characteristics). The con-
ventional view that patients with a prior failed transplant
are more prone to rejection may be based on data from
the 1980s [24], before current immunosuppressive agents
were available. Interrogation of data on 823 patients who
lost a kidney allograft to BK virus infection during 2004–
2008 has shown the one-year rejection rate after retrans-
plantation to be only 7% [25]. Furthermore, a multivari-
ate analysis of a French cohort has demonstrated that
although second transplants had a higher risk of late graft
failure (hazard ratio 2.18), there was no significant differ-
ence in the occurrence of acute rejection or steroid-
resistant acute rejection [23].
Multivariate analyses have not consistently shown pre-
transplant CMV-positive serology or CMV infection to be
a significant predictor for rejection (Table 1). The impact
of post-transplant CMV infection on risk of rejection
remains a matter for debate. It has recently been shown that
positive serostatus of the donor, particularly in CMV-sero-
positive recipients, negatively impacts long-term graft sur-
vival but not the occurrence of acute rejection [26]. Less
clear-cut is whether concomitant HIV infection raises the
risk of rejection: large registry analyses from 1996 [27] and
1997–2004 [28] observed no effect, but a more recent
meta-analysis of 254 patients from 12 case series [29], and
single-center reports [30–32], has reported high rates of
rejection by year 1 (31–55%). In a series of 150 HIV-positive
patients undergoing kidney transplantation at a single cen-
ter, the incidence of acute rejection at one and 3 years,
respectively, was 31% and 41% [32]. It is not clear why
rejection may be more frequent in HIV-positive recipients;
dysregulation of the immune system or inadequate immu-
nosuppression have been suggested as possible causes [33].
For hepatitis C virus (HCV) infection, recipient positivity
was not a predictor of acute rejection in the large USRDS
analysis by Cole et al. [3] or in multicenter [16] or single-
center studies [34,35], but in a single-center retrospective
analysis of 2269 patients over the period 1991–2007 which
assessed both recipient and donor serostatus, R+/D- status
was a significant predictor of acute rejection versus R-/D-
(adjusted hazard ratio 1.7, 95% CI 1.2–2.5) [36]. In a
multi-center study from Spain which assessed 4304 patients
transplanted during 1990–2002, the subpopulation of 587
HCV-positive patients exhibited a higher rate of acute
rejection than HCV-negative recipients but included a
higher proportion of retransplanted and immunized
patients [37]. Overall, there are insufficient data to establish
coinfection with HIV or HCV as significant predictors of
rejection.
No other clinical characteristics of the recipient appear
to exert a relevant effect on immunological risk. After
adjustment for confounding factors, diabetes mellitus
shows no association with acute rejection [4,14]. One
multivariate analysis of SRTR data from patients trans-
planted during 2002–2009 included coronary artery dis-
ease and peripheral vascular disease as potential
confounders and found no relation with risk of rejection
[21]. There are limited data to indicate that the cause of
end-stage renal disease [3] and duration of pretransplant
dialysis (using a cutoff point of 6 months) [4] are not
influential. Time on dialysis prior to transplantation,
however, is a relatively complex issue to explore as
although longer exposure to dialysis per se may not
increase the risk of acute rejection, medical consequences
such as greater risk of blood transfusion can promote
sensitization. Dialysis patients have been shown to have
increased antidonor T-cell alloreactivity [38].
One other area, which exerts a major impact on risk of
rejection, is patient adherence to the medication regimen.
In a recent review, Prendergast and Gaston identified a ser-
ies of factors associated with medication nonadherence
after kidney transplantation, including younger age
(<25 years), male gender, non-Caucasian ethnicity, poor
perception and understanding of treatment benefits, com-
plex regimens or more distressing side effects, longer time
post-transplant, and economic or physical impediments to
obtaining medication [22]. While the likelihood of nonad-
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herence is not generally taken into account when planning
the immunosuppressive regimen at the time of transplant,
use of intravenous immunosuppression (e.g., belatacept)
has been proposed as an option in young nonadherent
patients [39].
Recipient immunological characteristics
One of the most well-established risk factors for acute rejec-
tion is the degree of HLA mismatching. Hazard ratios in
the range of 1.39–3.78 have been described for one or more
HLA-A, -B and -DR mismatches [3,13,15], and 1.81–2.7
[14,18,19] for one or more HLA-DR mismatches. Discrep-
ancies in the impact of a mismatching may be due to dis-
parities in immunosuppressive strategies and population
characteristics. For example, ischemia–reperfusion injury is
greater in deceased donor grafts compared with living
donor grafts, increasing the expression of donor HLA anti-
gens, raising the alloimmune response and the risk of acute
rejection. However, while a single HLA-A, -B, or -DR mis-
match has not always been found to significantly predict
acute rejection [16,18], the association becomes irrefutable
as the number of HLA-A, -B, and -DR mismatches
increases [3,4,13]. The presence of pretransplant alloanti-
bodies against HLA class I and/or II has been shown con-
vincingly to increase the risk of acute rejection during the
first 3 months post-transplant, based on prospective data
collected by the Collaborative Transplant Study (CTS) (OR
2.53, P < 0.001) [40].
Recent years have seen intense interest in the role of DSA
as a predictor of rejection. A meta-analysis by Mohan et al.
[41] has confirmed that the presence of pretransplant
DSAs, be they class I, II, or both, is strongly associated with
the occurrence of acute antibody-mediated rejection (rela-
tive risk 1.98, 95% CI 1.36, 2.89). DSA titer correlates with
risk of acute antibody-mediated rejection [42]. A threshold
of 3000 for peak pretransplant DSA detected by the Lumin-
ex technique may be indicative of increased risk [43], but
this is not necessarily reproducible in different laboratories.
Suitable cutoff points using other detection techniques,
notably positive cross-match on flow cytometry in recent
or historical serum samples and a positive historical com-
plement-depended cytotoxicity (CDC) cross-match, have
not been established. Further data—including information
on different types of DSA such as C1q fixing—are required
for reliable risk stratification based on DSA levels.
The presence of PRA >0% has been a widely accepted
marker for acute rejection risk after kidney transplantation
[6] based on retrospective [16,18,19,44] and prospective
[45] data, and PRA level is uniformly included as a criteria
for ‘high-risk’ patients in clinical trials [8–12]. Unexpect-
edly, Cole et al. did not observe a significant association
between PRA >30% (11.9% of patients) and risk of acute
rejection in their USRDS population of 27 707 kidney
transplants from 1995 to 2002 [3], although multivariate
analyses in smaller populations have found an increase in
risk in the range of 1.2–2.7-fold using thresholds of >0%
[18], >15% [16] and >50% [19]. The risk associated with
PRA, however, is likely to be mediated by DSA, and as a
result, PRA level per se may in fact not be important. In a
retrospective analysis of 587 kidney transplants performed
at a single center, Dunn et al. [4] observed that PRA >0%
was not significantly related to either antibody-mediated or
cellular rejection in the absence of DSA. When DSA was
included in a multivariate model, PRA >0% was no longer
significantly associated with antibody-mediated rejection,
but of course different immunosuppressive regimens in the
high-and low-risk patients may have clouded the issue [4].
However, some sensitized patients, while DSA-negative, are
characterized by high levels of circulating antibodies against
non-HLA antigens such as autoantigens or major histo-
compatibility complex (MHC) class I-related chain A
(MICA), which can contribute to post-transplant rejections
[46]. Sánchez-Zapardiel et al. [47] recently observed in a
series of 727 kidney transplants that preformed anti-MICA
antibodies (present in 15% of patients) independently
increased the risk of acute rejection and enhanced the dele-
terious effect of positive PRA status early after transplanta-
tion. In addition, the presence of alloantigen-specific
memory B cells, in the context of no detectable circulating
DSAs prior to transplantation, poses a risk of post-trans-
plant rejections by promoting the activation of na€ıve T cells
[48]. New tests are under evaluation (B-cell ELISpot) for
the identification of such alloantigen-specific memory B
cells.
The CD30 molecule belongs to the tumor necrosis factor
receptor (TNF-R) superfamily. In activated T cells, the
membrane-bound CD30 molecule is proteolytically
cleaved, thereby generating a soluble form (sCD30), which
can be measured in serum. It has been suggested that pre-
or post-transplant levels of sCD30 represent a biomarker
for graft rejection associated with an impaired outcome for
transplanted patients [48]. Thus, sCD30 seems to reflect
the pretransplant activation status of the T cells and thereby
allows identification of high-risk recipients.
Memory T cells generated in response to environmental
stimuli (e.g., previous transplant, blood transfusion, viral
infections) become more prevalent with age and can cross-
react with alloantigens from the donor graft, despite no
previous exposure to tissue from that donor. The presence
of cross-reactive, donor-specific memory T cells increases
the risk of immunological injury to the graft. In a small ser-
ies of 19 deceased and living donor kidney transplant recip-
ients, Heeger et al. [49] demonstrated that the
pretransplant frequency of donor-specific memory T cells,
as assessed by levels of allospecific cytokines, correlated
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with the subsequent risk of acute rejection. More recently,
the same group retrospectively assessed 118 consecutive
recipients of a kidney allograft from a deceased donor aged
>50 years and found the incidence of acute rejection to be
36% vs. 14% in patients with or without donor-specific
lymphocytes (P = 0.009) [50]. Defining the allospecific
immune response prior to transplantation may in the
future contribute to identification of donor–recipient pairs
at high risk of rejection. Standardization and cross-valida-
tion of such assays have been recently performed, both in
Europe [51] and the USA [52].
Donor clinical characteristics
In the early 1990s, the one-year incidence of acute rejection
was approximately 10% lower in recipients of a kidney graft
from a living donor than a deceased donor [1], but the dif-
ference has since narrowed to only 1–2% [1,53] due to fac-
tors such as improved immunosuppression and closer
matching for deceased donor grafts. Living related dona-
tion does not appear to reduce the risk of acute rejection
versus living unrelated donation, despite a significantly
higher donor–recipient HLA disparity in recipients of a
graft from living unrelated donors [54,55].
Several multivariate analyses of risk factors for acute
rejection have included increased donor age as a potential
variable [13,14,16–18,56,57]. In addition, there is an associ-
ation between increased donor age and subclinical rejection
on protocol renal allograft biopsies [58]. In the majority of
cases, donor age was included as a continuous variable,
with no cutoff point [14,16–18,56,57], the exception being
a prospective single-center study of 739 patients which
reported donor age ≥65 years to be a significant predictor
for acute rejection [13]. Tullius et al. analyzed UNOS data
from 108 118 deceased donor kidney transplants during
1995–2008 with the aim of investigating the effect of donor
age on transplant outcomes [56]. They observed a signifi-
cant association between increasing donor age and acute
rejection, but this effect was less marked than for younger
recipient age. For example, the incidence of acute rejection
was 18.2% vs. 24.5% with donors aged 18–29 vs. 60–
69 years, compared with 28.7% vs. 15.7% for recipients in
the same age groups.
Donor gender per se has not been shown to influence
rates of rejection in two large retrospective cohorts [16,19],
although a prospective analysis of 739 living donor recipi-
ents undertaken to assess the effect of donor gender
observed that male donors were associated with a trend to
Table 2. Donor demographics and clinical characteristics as risk factors for acute rejection after kidney transplantation based on multivariate
analysis.
Reference Data source
Year of
transplant n
Older
donor age
Donor–recipient
demographic
mismatch
Brain death
(versus
circulatory
death) Cause of death
Tan et al. [62] Registry 1988–2006 188 508 – X (gender
mismatch)
– –
Ferrari et al. [63] Registry 1991–2006 2364 – X (age
mismatch)
– –
Tullius et al. [56] Registry 1995–2008 108 188 ✓ – – –
Naesens et al. [58] Single center 2004–2006 120 ✓ (subclinical) – – –
Øien et al. [13] Single center 1994–2004 739 ✓ (≥65 years) – – –
Quiroga et al. [14] Single center 1990–1998 518 ✓ – – X (trauma)
X (cardiovascular
disease)
Pallardo Mateu
et al. [16]
Multicenter 1990–1998 3365 X – – X (trauma)
Sanchez-Fructuoso
et al. [61]
Single center 1996–2002 372 – – – ✓ (cerebrovascular
disease)
Mota et al. [17] Single center 1985–1999 866 X – – ✓ (cardiovascular
disease)
Sagedal et al. [18] Single center 1994–1997 477 ✓ – ✓ (increased
in DBD)
–
De Fijter et al. [57] Single center 1983–1993 514 ✓ – –
Cutoff values for continuous variables are shown in italics.
✓, indicates that a significant association was observed; X, indicates that no significant association was observed; –, indicates that no assessment was
made; DBD, donation after brain death.
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fewer early acute rejection episodes (OR 0.80; 95% CI 0.73–
1.16; P = 0.063) [13].
It is difficult to disentangle the effect of expanded cri-
teria donor (ECD) grafts on rejection risk from the effect
of older donor age, as by definition, ECD grafts are from
older recipients. As ECD donors are typically matched to
older recipients [56], there may be no increase in immu-
nological risk of ECD donors overall, as reported by
multivariate analyses in two large series [59,60]. Specific
identification of acute rejection risk according to other
ECD characteristics, such as donor blood pressure and
kidney function, has not been performed.
The few studies that have investigated whether donor
cause of death influences risk of rejection have selectively
examined only one or two causes [14,16,17,61] (Table 2).
No comprehensive analysis has yet been undertaken. While
there are single-center data suggesting a significant associa-
tion between rejection and cardiovascular disease [17] or
cerebrovascular disease [61], methodological limitations
and the absence of corroborative data restrict their validity.
Donation after brain death, similarly, has not shown a con-
sistent relation with the risk of acute rejection [60,61,64–
69], although confounding variables make this difficult to
prove conclusively. Two large cohort studies on the UK
transplant registry had conflicting results regarding the risk
of acute rejection in kidneys donated after brain death or
circulatory death. In the first study [68], the incidence of
acute rejection at 3 months after transplantation was signif-
icantly higher in recipients of kidneys donated after brain
death than in recipients of kidneys donated after circulatory
death (24% vs. 17%, P < 0.0001), whereas in the more
recent study [69], acute rejection risk was not different
(13% vs. 12%). It remains unclear whether this discrepancy
results from evolving practice in immunosuppression or
relates to yet unidentified factors.
Donor–recipient demographic matching
In their large analysis of UNOS data, Tullius and colleagues
demonstrated convincingly that there is a pronounced
interaction between recipient and donor age. For example,
older recipients (>60 years) have a low risk of rejection that
is further reduced if they receive a graft from a younger
donor (18–20 years) (10–15%). Conversely, a younger reci-
pient (18–29 or 30–39 years) with a donor aged >60 years
has a 30–40% risk of acute rejection. Findings were con-
firmed by multivariate analysis. This age-specific analysis
may be more relevant than data from the Australia and
New Zealand Dialysis and Transplant Registry (ANZDA-
TA), which suggested that donor–recipient age mismatch-
ing does not affect risk of rejection [63]. In the ANZDATA
analysis, all donor–recipient pairs were grouped together if
the age difference was below -10, between -10 and 20,
20–29, or ≥30 years. Thus, for example, the category of -
10 years could include recipients aged 30 years or
>70 years, which is associated with widely differing rejec-
tion risk according to the UNOS data [56], casting doubt
on the results.
Mismatching of donor–recipient gender, in contrast,
does not seem relevant for acute rejection risk [62]
although it is a significant risk factor for graft loss even
after adjustment for sensitization status [62]. A retrospec-
tive study of 195 516 deceased donor recipients showed
that after adjustment for recipient and donor gender,
female recipients of male deceased donor kidneys exhibited
a small but significantly increased risk of graft failure and
patient mortality in the first year post-transplant compared
with all other recipient–donor gender combinations [70], a
finding partially confirmed elsewhere [71]. This effect may
Table 3. Qualitative assessment of pretransplant risk factors for acute
rejection in kidney transplant recipients. Variables considered most rele-
vant for assessment of immunological risk status are shown in italics.
Quality of evidence Impact
Recipient clinical characteristics
Younger age Good Strong*
Gender Moderate No
Black race Moderate Strong
High BMI Weak No
Retransplantation Moderate No
CMV infection Weak No
HIV infection Weak No
HCV infection Weak No
Recipient immunological characteristics
HLA mismatch Good Strong
Presence of anti-HLA antibodies Good Strong
Presence of pretransplant DSA Good Strong
DSA titer Moderate Strong
Panel reactive antibodies Moderate Moderate
Donor clinical characteristics
Deceased donor Moderate No
Older donor age Good Moderate†
Donor–recipient age matching Moderate Strong‡
Donor–recipient gender matching Moderate No
Extended criteria donor Poor No§
Cause of death Poor No
Nonheart-beating Moderate No
Transplant-related factors
Cold ischemia time Moderate Weak¶
Delayed graft function Good Strong
BMI, body mass index; CMV, cytomegalovirus; DSA, donor-specific anti-
bodies; ECD, expanded criteria donor; HCV, hepatitis C virus; HLA,
human leukocyte antigen.
*Various cutoff points, typically <45–50 years.
†Continuous effect.
‡Older donor/younger recipient confers higher risk.
§Older age in ECD donors confers higher risk.
¶If ≥24 h.
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be related to an alloimmune response to H-Y antigens
derived from the Y chromosome, which could act as a
minor histocompatibility antigen in female recipient/male
donor transplants.
Transplant-related factors
Delayed graft function (DGF) is one of the most
clear-cut risk factors for acute rejection after kidney trans-
plantation. It is estimated to confer an increased rejection
risk of between 38% and 81% compared to patients with
immediate function [14,16,17,19,72,73]. Yarlagadda et al.
[73] undertook a meta-analysis of 33 studies involving
151 594 kidney transplant recipients to investigate the rela-
tion between DGF and graft outcomes and found the rela-
tive risk of acute rejection with DGF to be 1.38 (95% CI
1.29–1.47), the most robust of the available analyses. Thus,
risk factors for DGF should be considered when planning
the immunosuppressive regimen. In an analysis of over
25 000 deceased donor kidney transplant patients in the
UNOS database, independent risk factors for DGF were
older recipient age, male gender, African American ethnic-
ity, elevated PRA level, long cold ischemia time, and diabe-
tes mellitus [74].Not all risk factors for DGF, however, are
independent risk factors for acute rejection (see above).
Longer cold ischemia time could potentially contribute
to the risk of rejection by exacerbating ischemia–reperfu-
sion injury [75] and increasing the risk of DGF [76]. Avail-
able analyses of cold ischemia time as a continuous variable
have not shown a significant association after adjustment
for confounding variables [14,16,18,19], but a relatively
high cutoff point may be required to demonstrate an effect.
In a study of UNOS data from 27 377 patients undertaken
to examine the association between obesity and outcomes,
Gore and colleagues found cold ischemia time ≥24 h to
be significantly associated with risk of acute rejection
(P = 0.002) [15].
Conclusion
It is not possible to establish conclusively the relative con-
tribution of different risk factors for acute rejection after
kidney transplantation. Adequately powered registry stud-
ies and meta-analyses based on recent patient cohorts have
not comprehensively evaluated risk factors using acute
rejection as the endpoint and are hampered by an absence
of data on biopsy-proven acute rejection. Single-center
studies, while offering more rigorous designs, have gener-
ally focused on only one risk factor and are necessarily
based on smaller populations. However, with these caveats
in mind, a qualitative assessment of the probable impact of
leading risk factors can be developed (Table 3). It seems
reasonable to propose that younger recipient age, African
American ethnicity, and older donor age be taken into
account when assessing immunological risk pretransplant,
complemented by increasing HLA mismatch, the presence
of HLA alloantibodies and PRA status, and the presence of
DSA (ideally with DSA titer). Taking these variables into
account at the time of transplant would provide a realistic
basis for planning an appropriate immunosuppression regi-
men in individual patients. This list does not, of course,
take into account post-transplant contributory factors, par-
ticularly adherence.
The accuracy of immunological risk assessment could be
improved by a well-planned registry analysis incorporating
these parameters into a model of risk factors for acute
rejection. Such an analysis would inevitably by limited by
the absence of data on biopsy-proven rejection and more
novel variables such as DSA titer, however, and it would be
helpful if registry data collection procedures could in the
future be expanded to include this information.
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